

infection and be used to treat HAV infected patients; development of transgenic animals for HAV vaccine production and testing.

HAVcr-1 has recently been molecularly cloned and its cDNA is available for further development. A Notice of Allowance has recently been issued on this case by the U.S. Patent and Trademark Office; foreign rights are also available. This invention is available for licensing on an exclusive or nonexclusive basis.

Dated: January 9, 1997.

Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.

[FR Doc. 97-1532 Filed 1-21-97; 8:45 am]

BILLING CODE 4140-01-M

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for U.S. companies and may also be available for licensing.

ADDRESS: Licensing information and copies of the U.S. patent applications listed below may be obtained by contacting the indicated licensing specialist at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

2,2'-Bipyridyl, a Ferrous Chelator, Prevents Vasospasm in a Primate Model of Subarachnoid Hemorrhage

LL Horky (NINDS)

Serial No. 08/672,060 filed 26 Jun 96

Licensing Contact: Stephen Finley, Ph.D., 301/496-7735 ext 215

Subarachnoid hemorrhage (SAH) occurs in 28,000 people per year in North America. Symptomatic vasospasm occurs in the majority of individuals suffering SAH and is the most common cause of morbidity and mortality in patients reaching neurological care. Specifically, vasospasm causes cerebral ischemia or

stroke, and the prevention of vasospasm could prevent stroke and death as well as allow physicians more freedom in scheduling surgery when the operative risks are lower.

Intravenous administration of 2,2'-bipyridyl successfully prevented vasospasm in a reliable primate model of subarachnoid hemorrhage. Bipyridyl may provide a safe, cost-effective and reliable therapy for vasospasm in the clinical setting. Additional ferrous chelates, which may also prove effective, are also embodied in the invention. (portfolio: Central Nervous System—Therapeutics, neurological, stroke)

Interleukin-4 Stimulated T-Lymphocyte Cell Death for the Treatment of Autoimmune Diseases, Allergic Disorders and Graft Rejection

MJ Lenardo, SA Boehme, J Critchfield (NIAID)

Serial No. 08/348,286 filed 30 Nov 94

Licensing Contact: Jaconda Wagner, J.D., 301/496-7735 ext 284

The discovery that interleukin-4 (IL-4) predisposes T lymphocytes to programmed cell death (apoptosis) allows for a novel method of therapeutic intervention in diseases caused by the action of IL-4-responsive T cells. Specifically, the therapy induces the death of a subpopulation of T lymphocytes that are capable of causing disease. Current therapies may cause general death or suppression of immune responses involving T-cells, severely comprising a patient's immune system. This treatment affects only the subset of T cells that react with a specified antigen, thereby leaving a patient's immune system uncompromised. This invention is useful in treating allergies and HIV complications. Both fields are available for licensing (portfolio: Internal Medicine—Therapeutics, anti-inflammatory)

Interleukin-2 Stimulated T-Lymphocyte Cell Death for the Treatment of Autoimmune Diseases, Allergic Disorders and Graft Rejection

MJ Lenardo (NIAID)

Serial No. 08/482,724 filed 07 Jun 95

Licensing Contact: Jaconda Wagner, J.D., 301/496-7735 ext 284

T-Cell apoptosis induced by administration of IL-2 and antigen offers an important new treatment for allergic disorders, which are due to the effects of antigen-activated T-cells. Antigen-activated T-cells cause the release of harmful lymphokines and the production of immunoglobulin E by B cells. Presently available methods for

treating allergies have limitations because they are nonspecific in their action and have side effects and limited efficacy. IL-2 and antigen stimulates the programmed death of only antigen-specific T-cells while leaving the rest of the patient's T-cells and other immune cells intact. This invention is also useful in treating HIV. Both fields of use, allergies and HIV, are available for licensing. (portfolio: Internal Medicine—Therapeutics, anti-inflammatory)

Dated: January 13, 1997.

Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.

[FR Doc. 97-1534 Filed 1-21-97; 8:45 am]

BILLING CODE 4140-01-M

Division of Research Grants; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meetings:

Purpose/Agenda: To review individual grant applications.

Name of SEP: Behavioral and Neurosciences.

Date: January 20, 1997.

Time: 3:30 p.m.

Place: NIH, Rockledge 2, Room 5168 Telephone Conference.

Contact Person: Dr. Jane Hu, Scientific Review Administrator, 6701 Rockledge Drive, Room 5168, Bethesda, Maryland 20892, (301) 435-1245.

This notice is being published less than 15 days prior to the above meetings due to the urgent need to meet timing limitations imposed by the grant review and funding cycle.

Name of SEP: Biological and Physiological Sciences.

Date: February 4, 1997.

Time: 2:00 p.m.

Place: NIH, Rockledge 2, Room 6170 Telephone Conference.

Contact Person: Dr. Dennis Leszczynski, Scientific Review Administrator, 6701 Rockledge Drive, Room 6170, Bethesda, Maryland 20892, (301) 435-1044.

Name of SEP: Multidisciplinary Sciences.

Date: February 24-26, 1997.

Time: 8:00 a.m.

Place: Doubletree Hotel, Rockville, Maryland.

Contact Person: Dr. Dharam Dhindsa, Scientific Review Administrator, 6701 Rockledge Drive, Room 5206, Bethesda, Maryland 20892, (301) 435-1174.

Name of SEP: Clinical Sciences.

Date: February 24-26, 1997.

Time: 8:30 a.m.

Place: Hyatt Regency, Bethesda, Maryland.